Sage Therapeutics (SAGE) PT Raised to $105 at Cowen Following WATERFALL Data

June 15, 2021 12:07 PM EDT
Get Alerts SAGE Hot Sheet
Price: $32.28 -0.06%

Rating Summary:
    14 Buy, 12 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 1 | Down: 1 | New: 0
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Cowen analyst Ritu Baral raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $105.00 (from $100.00) while maintaining an Outperform rating following trial data.

The analyst commented, "This AM Sage released topline data from their Ph3 WATERFALL study of 50mg zuranolone in MDD, which met its primary endpoint in reduction in HAMD at Day 15 (p=0.0141) and demonstrated favorable safety. Despite the modest improvement in HAMD at Day 15, we view this study as successful and are optimistic on zuranolone's potential approval in MDD. We have increased out PT to $105, remain Outperform."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cowen & Co